Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02574741 · ClinicalTrials.gov registry record · Phase 2
Combination Treatment for Augmenting Language in Children With ASD
A Phase 2 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT02574741 is a Phase 2 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 58 participants.
The verdict
NCT02574741, a Phase 2 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
The study will consist of two main elements: the enrollment of 72 children aged 6-11 years with ASD and low language competency to receive a thrice-weekly one hour language intervention for 12 weeks; and, beginning at the same time, subjects will be equally randomized to receive either aripiprazole (Abilify) (flexibly dosed from 2-10 mg per day) or placebo for 12 weeks.
Interventions
- DRUG Placebo
- DRUG Aripiprazole
- BEHAVIORAL Behavioral Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2012-06 |
| Est. Completion | 2019-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02574741
The ClinicalTrials.gov registry entry for NCT02574741 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02574741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02574741 about?
NCT02574741 is a clinical study titled "Combination Treatment for Augmenting Language in Children With ASD". The study will consist of two main elements: the enrollment of 72 children aged 6-11 years with ASD and low language competency to receive a thrice-weekly one hour language intervention for 12 weeks; and, beginning at the same time, subjects will be equally randomized to receive either aripiprazole ...
What is the current status of trial NCT02574741?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2012-06. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02574741?
The interventions under investigation include: Placebo (DRUG), Aripiprazole (DRUG), Behavioral Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT02574741?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.